Literature DB >> 12601357

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response.

Kazushi Sugimoto1, Jason Stadanlick, Fusao Ikeda, Colleen Brensinger, Emma E Furth, Harvey J Alter, Kyong-Mi Chang.   

Abstract

This study was performed to examine the immunologic basis for the apparent ethnic difference in clinical outcome of hepatitis C virus (HCV) infection between African Americans (AA) and Caucasian Americans (CA). To this end, we recruited 99 chronically HCV-infected and 31 spontaneously HCV-cleared subjects for clinical, virologic, and immunologic analysis. In particular, CD4-proliferative T-cell response to genotype 1-derived HCV antigens (core, NS3-NS5) was examined in 82 patients chronically infected with genotype 1 (54 AA, 28 CA) and in all HCV-cleared subjects (14 AA, 17 CA). HCV-specific Th1 response also was examined in 52 chronic and 13 recovered subjects. Our results showed that HCV clearance was associated with a vigorous HCV-specific Th1 response irrespective of ethnic origin. Although the HCV-specific CD4 T-cell response clearly was weaker during chronic infection, AA ethnicity in this setting was associated with a significantly greater CD4-proliferative T-cell response to HCV, particularly to the nonstructural antigens (22% AA vs. 0% CA, P =.007) as well as better clinical parameters of liver disease. Interestingly, most HCV-specific CD4 T-cell proliferative responses in AA patients were unaccompanied by concurrent interferon gamma (IFN-gamma) production, suggesting a dysregulated virus-specific, CD4 T-cell effector function during chronic HCV infection. In conclusion, our results suggest that host ethnicity does influence the clinical outcome and antiviral T-cell response during HCV infection. AA ethnicity is associated with a more robust antiviral CD4 T-cell response than CA ethnicity, although these T cells are limited in direct virus or disease control due to their dysfunctional nature.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601357     DOI: 10.1053/jhep.2003.50103

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.

Authors:  Savita Srivastava; Maria Bertagnolli; James H Lewis
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

2.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

3.  Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto
Journal:  Dig Dis Sci       Date:  2016-04-08       Impact factor: 3.199

4.  Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Authors:  Keisuke Ojiro; Xiaowang Qu; Hyosun Cho; Jang-June Park; Annelise Vuidepot; Nikolai Lissin; Peter E Molloy; Alan Bennett; Bent K Jakobsen; David E Kaplan; James L Riley; Kyong-Mi Chang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

6.  Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.

Authors:  Ping An; Chloe L Thio; Gregory D Kirk; Sharyne Donfield; James J Goedert; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

Review 7.  Chronic hepatitis C in African Americans and other minority groups.

Authors:  Jaquelyn Fleckenstein
Journal:  Curr Gastroenterol Rep       Date:  2004-02

8.  Hepatitis C and innate immunity: recent advances.

Authors:  Gyongyi Szabo; Angela Dolganiuc
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

9.  Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans.

Authors:  Rebecca A Harris; Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Malek Kamoun; Kyong-Mi Chang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

10.  Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.

Authors:  Marcos Pérez-Losada; David Posada; Miguel Arenas; David V Jobes; Faruk Sinangil; Phillip W Berman; Keith A Crandall
Journal:  Retrovirology       Date:  2009-07-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.